S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
S&P 500   3,852.36
DOW   32,920.46
QQQ   306.18
Route to Super Bowl dangerous for Mexico's avocado haulers
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Iraqi currency crash halts after meeting with U.S. official
Europe bans Russian diesel, other oil products over Ukraine
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Gas prices dip in NJ, around nation as cold weather returns
It wasn’t me: Ex-UK PM Truss blames 'system' for her failure
A gold storm is coming… (Ad)
How will EU ban and West's price cap on Russian diesel work?
EU migration impasse leaves many refugees out in the cold
NASDAQ:CRBP

Corbus Pharmaceuticals - CRBP Stock Forecast, Price & News

$0.17
0.00 (0.00%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.17
$0.19
50-Day Range
$0.11
$0.19
52-Week Range
$0.10
$0.62
Volume
1.95 million shs
Average Volume
1.51 million shs
Market Capitalization
$21.49 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Corbus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
2.51% of Float Sold Short
Dividend Strength
N/A
Sustainability
-0.65
Upright™ Environmental Score
News Sentiment
0.00mentions of Corbus Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.64 out of 5 stars

CRBP stock logo

About Corbus Pharmaceuticals (NASDAQ:CRBP) Stock

Corbus Pharmaceuticals Holdings, Inc. is a phase 3 clinical-stage pharmaceutical company, which focuses on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its products include candidate, Lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus. The company was founded in April 2009 and is headquartered in Norwood, MA.

Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
Corbus Pharmaceuticals Holdings, Inc. (CRBP)
See More Headlines
Receive CRBP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Corbus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CRBP Company Calendar

Last Earnings
11/08/2022
Today
2/05/2023
Next Earnings (Estimated)
3/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRBP
Employees
41
Year Founded
2009

Profitability

Net Income
$-45,640,000.00
Pretax Margin
-36,209.27%

Debt

Sales & Book Value

Annual Sales
$880,000.00
Book Value
$0.55 per share

Miscellaneous

Free Float
115,008,000
Market Cap
$21.49 million
Optionable
Optionable
Beta
2.14

Social Links


Key Executives

  • Yuval CohenYuval Cohen
    Chief Executive Officer & Director
  • Craig Millian
    Chief Operating Officer
  • Sean F. Moran
    Chief Financial & Accounting Officer
  • Rachael Brake
    Chief Scientific Officer
  • Brian Walsh
    Vice President-Corporate Development













CRBP Stock - Frequently Asked Questions

How have CRBP shares performed in 2023?

Corbus Pharmaceuticals' stock was trading at $0.1105 at the beginning of the year. Since then, CRBP stock has increased by 55.2% and is now trading at $0.1715.
View the best growth stocks for 2023 here
.

When is Corbus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 14th 2023.
View our CRBP earnings forecast
.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) released its quarterly earnings results on Tuesday, November, 8th. The biopharmaceutical company reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.01.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Pinnacle Associates Ltd. (0.58%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Barbara White, Craig Stuart Millian, Robert Paul Discordia, Sean F Moran and Yuval Cohen.
View institutional ownership trends
.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.17.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals (NASDAQ:CRBP) has a market capitalization of $21.49 million and generates $880,000.00 in revenue each year. The biopharmaceutical company earns $-45,640,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The official website for the company is www.corbuspharma.com. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at ir@corbuspharma.com, or via fax at 617-663-6085.

This page (NASDAQ:CRBP) was last updated on 2/5/2023 by MarketBeat.com Staff